Evidence map›Paper›PMID 34549040›Full record

ArticleAnnals of surgical treatment and research2021

Meta-analysis of transanal versus laparoscopic total mesorectal excision for rectal cancer: a 'New Health Technology' assessment in South Korea.

Sun-Ho Kwon, Yea-Il Joo, Seon Hahn Kim, Dae Ho Lee, Jeong-Heum Baek, Soon Sup Chung, Ji-Yeon Shin, Chang Soo Eun, Nam Kyu Kim

Open access · diamondAbstract read
In one paragraph

Article in Annals of surgical treatment and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Sun-Ho KwonDivision for New Health Technology Assessment, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0003-1592-0638
Yea-Il JooDivision for New Health Technology Assessment, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0003-4184-662X
Seon Hahn KimTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0002-4526-5147
Dae Ho LeeTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0002-9749-4638
Jeong-Heum BaekTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0001-9124-8041
Soon Sup ChungTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0003-0921-8228
Ji-Yeon ShinTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0001-5434-0359
Chang Soo EunTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0001-6533-9644
Nam Kyu KimTaTME Assessment Committee, National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.ORCID https://orcid.org/0000-0003-0639-5632
National Evidenc- based healthcare Collaborating Agency · KREwha Womans University · KRGachon University · KRHanyang University Guri Hospital · KRKorea University · KRKyungpook National University · KRUlsan College · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUnder the South Korea's unique health insurance structure, any new surgical technology must be evaluated first by the government in order to consider whether that particular technology can be applied to patients for further clinical trials as categorized as 'New Health Technology,' then potentially covered by the insurance sometime later. The aim of this meta-analysis was to assess the safety and efficacy of transanal total mesorectal excision (TaTME) for rectal cancer, activated by the National Evidence-based Healthcare Collaborating Agency (NECA) TaTME committee.

methodsWe systematically searched Ovid-MEDLINE, Ovid-Embase, Cochrane, and Korean databases (from their inception until August 31, 2019) for studies published that compare TaTME with laparoscopic total mesorectal excision (LaTME). End-points included perioperative and pathological outcomes.

resultsSixteen cohort studies (7 for case-matched studies) were identified, comprising 1,923 patients (938 TaTMEs and 985 LaTMEs). Regarding perioperative outcomes, the conversion rate was significantly lower in TaTME (risk ratio, 0.19; 95% confidence interval, 0.11-0.34; P < 0.001); whereas other perioperative outcomes were similar to LaTME. There were no statistically significant differences in pathological results between the 2 procedures.

conclusionOur meta-analysis showed comparable results in preoperative and pathologic outcomes between TaTME and LaTME, and indicated the benefit of TaTME with low conversion. Extensive evaluations of well-designed, multicenter randomized controlled trials are required to come to unequivocal conclusions, but the results showed that TaTME is a potentially beneficial technique in some specific cases. This meta-analysis suggests that TaTME can be performed for rectal cancer patients as a 'New Health Technology' endorsed by NECA in South Korea.

Indexed as

Colorectal neoplasmsLaparoscopic total mesorectal excisionMeta-analysisSystematic reviewTransanal total mesorectal excision

Identifiers

PMID34549040
PMCPMC8424436
OpenAlexW3197930289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.